publicFounded 2013
Editas Medicine
Funding Summary
Total Funding
$700M+
Latest Valuation
~$500M (public market cap)
About
Gene editing company focused on developing transformative medicines using CRISPR. Lead program EDIT-301 (reni-cel) for sickle cell disease. Also pursuing in vivo editing for ocular diseases.
Products
in-vivo-gene-editingreni-cel
Recent Developments
Recent developments are auto-populated from tagged articles in the Newsfeed. Browse all news →